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Once daily administration of the 
SGLT2 inhibitor, empagliflozin, 
attenuates markers of renal fibrosis 
without improving albuminuria in 
diabetic db/db mice
Linda A. Gallo1, Micheal S. Ward1, Amelia K. Fotheringham1, Aowen Zhuang1, 
Danielle J. Borg1, Nicole B. Flemming1, Ben M. Harvie2, Toni L. Kinneally3, Shang-
Ming Yeh4, Domenica A. McCarthy1, Hermann Koepsell5, Volker Vallon6,7, Carol Pollock8, 
Usha Panchapakesan8 & Josephine M. Forbes1,9
Blood glucose control is the primary strategy to prevent complications in diabetes. At the onset of 
kidney disease, therapies that inhibit components of the renin angiotensin system (RAS) are also 
indicated, but these approaches are not wholly effective. Here, we show that once daily administration 
of the novel glucose lowering agent, empagliflozin, an SGLT2 inhibitor which targets the kidney to 
block glucose reabsorption, has the potential to improve kidney disease in type 2 diabetes. In male 
db/db mice, a 10-week treatment with empagliflozin attenuated the diabetes-induced upregulation of 
 profibrotic gene markers, fibronectin and transforming-growth-factor-beta. Other molecular (collagen 
IV and connective tissue growth factor) and histological (tubulointerstitial total collagen and glomerular 
collagen IV accumulation) benefits were seen upon dual therapy with metformin. Albuminuria, 
urinary markers of tubule damage (kidney injury molecule-1, KIM-1 and neutrophil gelatinase-
associated lipocalin, NGAL), kidney growth, and glomerulosclerosis, however, were not improved with 
empagliflozin or metformin, and plasma and intra-renal renin activity was enhanced with empagliflozin. 
In this model, blood glucose lowering with empagliflozin attenuated some molecular and histological 
markers of fibrosis but, as per treatment with metformin, did not provide complete renoprotection. 
Further research to refine the treatment regimen in type 2 diabetes and nephropathy is warranted.
Diabetic nephropathy accounts for 35–40% of new cases of end-stage renal disease in the developed world1,2. 
A major risk factor for the vascular complications of diabetes is chronic elevations in blood glucose concentra-
tions (hyperglycemia) but there is no guarantee that glycemic control will prevent the onset and progression of 
micro- and/or macrovascular diseases3–6. At the first clinical sign of renal impairment (albuminuria), inhibitors 
of the renin-angiotensin system (RAS) are administered but they only slow progression of the disease4. Therefore, 
anti-diabetic strategies that effectively control blood glucose levels and prevent the onset and progression of dia-
betic nephropathy are in great demand.
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Sodium-dependent glucose transporter (SGLT)-2 inhibitors, a new anti-diabetic strategy, target the renal 
proximal tubules to block glucose reabsorption, thereby enhancing urinary glucose excretion and conferring 
anti-hyperglycemic effects. They are indicated for use in individuals with type 2 diabetes (provided kidney func-
tion is at least moderate) and are under clinical investigation as an add-on to exogenous insulin in type 1 diabetes. 
Clinical studies with SGLT2 inhibitors have reported reductions in fasting plasma glucose and glycated hemoglo-
bin (HbA1c) levels (0.7–0.8%) compared to placebo and other glucose lowering strategies7–11, and a reduction in 
cardiovascular mortality in individuals with type 2 diabetes and high cardiovascular risk12.
Under normal conditions, glucose is almost completely reabsorbed from the urinary filtrate by secondary 
active co-transporters located on the apical membrane, SGLT2 and SGLT1, in the early and late proximal tubule, 
respectively13. SGLT2 is responsible for the majority (up to 97%) of glucose reabsorption, while SGLT1 reabsorbs 
the majority of remaining luminal glucose. At the basolateral side, GLUT2 is responsible for the majority of glu-
cose transport from the cells into the interstitium and peritubular circulation. In diabetes, the maximal threshold 
for glucose reabsorption is increased14,15. This contributes to hyperglycemia and, potentially, diabetic nephropa-
thy via proximal tubular glucotoxicity.
While there is much focus on the role of glomeruli, tubulointerstitial changes more closely correlate with the 
clinical progression of nephropathy in diabetes16–18. Previous studies using human proximal tubular cells (HK2) 
reported that SGLT2 inhibition decreased the production of inflammatory and fibrotic markers induced by high 
glucose19. These in vitro findings suggest that SGLT2 inhibitors may provide renoprotection in diabetes by avert-
ing glucose from entering proximal tubule cells20,21. However, in recent preclinical studies, renoprotection with 
SGLT2 inhibition has been seen only when blood glucose levels were markedly improved20–25. Thus, the effect of 
SGLT2 inhibition on early kidney growth, inflammation, and fibrosis was proposed to result from blood glucose 
lowering21. The effect of SGLT2 inhibition on diabetic nephropathy, independent of blood glucose lowering, was 
assessed in diabetic eNOS knockout mice26. Blood glucose levels were matched between diabetic groups using 
insulin (group means > 20 mmol/L) and, unlike an angiotensin receptor blocker, empagliflozin did not provide 
renoprotection. These data highlight that, in models of early diabetic nephropathy, renoprotection from hyper-
glycemia may be afforded only when circulating glucose levels and/or the activity of the RAS are sufficiently 
decreased.
In this study, we aimed to determine whether the administration of an SGLT2 inhibitor, empagliflozin, 
improves early manifestations of diabetic nephropathy in the db/db mouse model of type 2 diabetes. This model 
harbors a spontaneous mutation of the leptin receptor and is characterized by polyphagia, obesity, insulin resist-
ance, hyperglycemia, pancreatic β -cell failure, and kidney and cardiovascular complications that are akin to type 
2 diabetes in humans. We further aimed to determine whether the renoprotection offered by empagliflozin was 
associated with lowering of blood glucose concentrations, intrarenal RAS activity, and/or glucose content within 
kidney cortices. Whether these renal benefits were superior to the first-line, glucose-lowering therapy for type 2 
diabetes, metformin, and/or additive upon empagliflozin and metformin dual therapy, were also assessed.
Results
Body weight and metabolic parameters. In this study, db/db and db/m littermates were treated with 
empagliflozin (10 mg/kg/day) or vehicle by single daily oral gavage for 10 weeks. Two additional db/db groups 
were included and treated with the first-line anti-diabetic agent, metformin (250 mg/kg/day), or empagliflozin 
and metformin co-therapy (as per mono-therapy dosages). At treatment commencement (baseline; 10 weeks of 
age), db/db mice were ~14 g heavier (>1.5-fold, Table 1) with higher fasting blood and plasma glucose concen-
trations compared to non-diabetic db/m mice (Fig. 1a,c). Between weeks five and 10 of treatment, db/db mice 
administered with vehicle or metformin lost 3.0 and 4.4 g, respectively, whilst empagliflozin monotherapy main-
tained body weight and co-treated mice gained 3.1 g (Table 1). This may relate to differences in circulating insulin 
Treatment 
duration db/m vehicle db/m empa db/db vehicle db/db empa db/db met
db/db 
empa + met
Body weight (g) Baseline 27.0 ± 0.6 27.3 ± 0.4 41.9 ± 0.9* 42.1 ± 1.0* 40.8 ± 0.9* 41.0 ± 1.0*
5 weeks 27.8 ± 0.6 27.5 ± 0.4 42.3 ± 1.2* 46.1 ± 1.2* 43.7 ± 1.2* 47.6 ± 1.0*,†
10 weeks 28.8 ± 0.7 28.5 ± 0.3 39.3 ± 1.3* 47.4 ± 1.9*,†,δ 39.3 ± 2.2* 50.7 ± 1.3*,†,δ
Kidney weight (g/mm tibia 
length × 10−2) 10 weeks 1.48 ± 0.06 1.50 ± 0.03 1.87 ± 0.06
* 1.77 ± 0.05*,δ 2.12 ± 0.09*,ε 1.84 ± 0.05*,δ
Food consumption (g/24 h) 2 weeks 4.95 ± 0.47 5.27 ± 0.32 9.29 ± 1.22* 9.10 ± 0.99* 8.54 ± 0.55* 9.51 ± 0.97*
6 weeks 5.30 ± 0.34 6.27 ± 0.55 9.25 ± 1.00* 9.91 ± 1.26* 10.05 ± 1.09* 9.13 ± 0.78*
Water consumption (ml/24 h) 2 weeks 4.24 ± 0.66 4.80 ± 0.49 19.78 ± 2.00* 21.74 ± 2.76* 17.18 ± 1.55* 16.43 ± 0.95*
6 weeks 4.10 ± 0.28 5.62 ± 0.80∧ 14.42 ± 1.82* 14.65 ± 2.51* 19.10 ± 2.35* 15.25 ± 1.43*
Urine production (ml/24 h) 2 weeks 0.26 ± 0.08 0.65 ± 0.15∧ 13.18 ± 1.78* 14.07 ± 2.59* 11.40 ± 1.84* 10.84 ± 1.70*
6 weeks 0.36 ± 0.08 0.82 ± 0.15# 12.89 ± 1.99* 13.48 ± 3.16* 13.19 ± 1.92* 9.80 ± 1.61*
Table 1.  Body and kidney weight, food and water consumption, and urine output. Data are means ± SEM 
(n = 6–11/group). *P < 0.05 vs db/m vehicle, †P < 0.05 vs db/db vehicle, δP < 0.05 vs db/db metformin within 
each time point by one-way ANOVA and Tukey’s post hoc. #P < 0.05 vs db/m vehicle, ∧P = 0.05–0.07 (trend) vs 
db/m vehicle, εP = 0.05–0.07 (trend) vs db/db vehicle within that time point by Student’s unpaired t-test. N.B. 
Body weight between treatment weeks 5 and 10, within each group, were compared by Student’s paired t-test 
and described in the Results section.
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levels (described below in Oral glucose tolerance test (OGTT); Fig. 2). For db/m mice, both vehicle- (P = 0.07) 
and empagliflozin-treated groups gained 1.0 g between weeks five and 10 of treatment (Table 1). At 10 weeks of 
treatment (20 weeks of age), db/db mice treated with empagliflozin were 8 to 11 g heavier than vehicle- and met-
formin-only-treated mice (Table 1).
Blood and plasma glucose concentrations were measured 20–24 h after the previous day’s therapy. Three days 
after the commencement of treatment, all mice treated with empagliflozin had lower fasting blood glucose lev-
els compared to db/db vehicle and all intervention arms had considerable reductions from baseline (Fig. 1a,b). By 
the study end, SGLT2 inhibitor monotherapy lowered fasting plasma glucose levels to 18 mmol/L compared to 
27 mmol/L in db/db vehicle (Fig. 1c). In addition, glycated hemoglobin was restored to non-diabetic levels, achieving 
6.6% compared to 9.6% in db/db vehicle (Fig. 1e). Co-therapy with metformin provided modest incremental bene-
fits, lowering fasting plasma glucose to 16 mmol/L, which was also reduced from baseline, and glycated hemoglobin 
to 5.7% (Fig. 1c–e). Metformin monotherapy tended to reduce fasting plasma glucose (20 mmol/L) and glycated 
hemoglobin (8.0%) compared to db/db vehicle (P = 0.079 and P = 0.062, respectively, Fig. 1c,e).
All db/db mice consumed more food and water, and produced more urine compared to db/m when assessed 
at two and six weeks into the treatment period (Table 1). There were no effects of treatment on food intake but, in 
the db/m mice, empagliflozin increased water consumption at six weeks (P = 0.066) and urine output at both ages 
(two weeks P = 0.055, Table 1).
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Figure 1. Circulating glucose levels. (a,b) Fasted blood glucose at baseline and three days after treatment 
start, (c,d) fasted plasma glucose at baseline and treatment end, and (e) glycated hemoglobin at treatment end 
in db/m (open) and db/db (grey) mice. Circles (ο ) vehicle-treated; squares (◽) empagliflozin-treated; triangles 
(▵) metformin-treated; and diamonds (⬨) empagliflozin + metformin co-treated. Data are means ± SEM 
(n = 5–11). (a,c,e): *P < 0.05 vs db/m vehicle, †P < 0.05 vs db/db vehicle, δP < 0.05 vs db/db metformin within a 
time point by one-way ANOVA and Tukey’s post hoc. Comparisons by Student’s unpaired t-test: significance 
denoted by solid lines and trends denoted by dashed lines. (b,d): #P < 0.05 delta change (▵) from baseline by 
Student paired t-test. N.B. (a,b): Some mice exceeded the upper limit of the glucometer, in which case the 
recorded blood glucose value was 33.3 mmol/L. Differences from baseline may therefore be underestimated.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:26428 | DOI: 10.1038/srep26428
Oral glucose tolerance test (OGTT). An OGTT was performed on all mice 20–24 h after the previous 
day’s treatment. Compared to db/m, all db/db mice had elevated plasma glucose concentrations for the duration of 
the OGTT resulting in a higher area under the glucose curve (AUCglucose, Fig. 2a,b). Empagliflozin monotherapy 
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Figure 2. Oral glucose tolerance. (a) Plasma glucose concentrations over time, (b) area under glucose curve; 
AUCglucose, (c) plasma insulin concentrations over time, (d) area under insulin curve; AUCinsulin, and  
(e) insulinogenic index; AUCinsulin:glucose 0–30 mins in response to an oral glucose bolus (2 g/kg body weight) 
and (f) fasted plasma glucose-to-insulin ratio (t = 0 mins) in db/m (open) and db/db (grey) mice. Circles (ο)  
vehicle-treated; squares (◽) empagliflozin-treated; triangles (▵) metformin-treated; and diamonds (⬨) 
empagliflozin + metformin co-treated. Data are means ± SEM (n = 6–11). *P < 0.05 vs db/m vehicle, †P < 0.05 
vs db/db vehicle, δP < 0.05 vs db/db metformin, ΨP < 0.05 vs all other db/db groups by one-way ANOVA and 
Tukey’s post hoc. Comparisons by Student’s unpaired t-test: significance denoted by solid lines and trends 
denoted by dashed lines.
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reduced plasma glucose levels at baseline and at 60 and 120 mins after the glucose bolus compared to vehicle 
db/db mice, resulting in a reduced AUCglucose (Fig. 2a,b). Co-therapy decreased plasma glucose concentra-
tions at baseline, and at 15, 60, and 120 mins of the OGTT, and reduced AUCglucose compared to vehicle- and 
metformin-treated db/db mice (Fig. 2a,b). Metformin monotherapy did not improved glucose tolerance during 
the OGTT (Fig. 2a,b).
Plasma insulin concentrations were increased throughout the OGTT in co-treated mice and at specific time 
points (0, 15, 30, and 60 mins) in empagliflozin mono-treated mice compared to db/m (Fig. 2c). Co-therapy 
also resulted in elevated plasma insulin levels throughout the OGTT when compared to diabetic vehicle- and 
metformin-treated mice, whilst empagliflozin increased insulin at baseline and 15 mins only (Fig. 2c). Vehicle-, 
empagliflozin-, and co-treated diabetic mice had elevated area under the insulin curve (AUCinsulin) compared to 
non-diabetic and this difference was most pronounced for the latter, which also had enhanced insulin response 
when compared to all other db/db groups (Fig. 2d). Vehicle- and metformin-treated db/db mice exhibited a 
50–60% reduction in the insulinogenic index (AUCinsulin:glucose 0–30 mins), and empagliflozin, as a single and dual 
therapy with metformin, restored and further increased this index compared to db/m levels, respectively (Fig. 2e). 
Fasting plasma glucose-to-insulin ratio was reduced in the co-treated mice when compared to vehicle- and 
metformin-treated diabetic mice as well as non-diabetic db/m mice (Fig. 2f), indicative of reduced insulin sensi-
tivity. Empagliflozin mono-therapy also tended to reduce this ratio when compared to the metformin-treated dia-
betic arm (P = 0.089, Fig. 2f). HOMA-IR was elevated in all diabetic mice and exacerbated in the co-treated group 
(see Supplementary Fig. S1a). Insulin positivity within pancreatic islets was not different between non-diabetic 
and diabetic vehicle-treated mice (see Supplementary Fig. S1b). Co-therapy, however, increased insulin positive 
staining in db/db mice compared to db/m vehicle and other diabetic groups, whilst metformin reduced insulin 
positivity compared to vehicle-treated counterparts (see Supplementary Fig. S1b). Empagliflozin increased islet 
insulin content when administered to db/m mice (see Supplementary Fig. S1b).
Renal glucose handling, and expression of glucose transporters and gluconeogenic 
enzymes. The predicted filtered glucose load, assessed after eight weeks of treatment, was increased in all db/
db mice (Fig. 3a,b). Empagliflozin (mono- and co-therapy) reduced the filtered glucose load by 45% compared 
to db/db vehicle, owing to a similar reduction in fasted plasma glucose levels (Fig. 3a). In db/db mice treated with 
empagliflozin monotherapy, reduced filtered glucose load was also mediated by a modest reduction in glomerular 
filtration rate (GFR; P = 0.059, Fig. 3b). All db/db mice had glucosuria, excreting ~1500 mg glucose into their urine 
each day, compared with < 0.2 mg in db/m vehicle (Fig. 3c). Empagliflozin in non-diabetic mice increased urinary 
glucose excretion to > 80 mg per day (Fig. 3c) without affecting circulating glucose concentrations compared to 
vehicle counterparts (see above; Fig. 1). In mice with diabetes, empagliflozin monotherapy caused a left-ward shift 
in the relationship between plasma glucose level and urinary glucose, indicating that urinary glucose excretion 
was greater for any given concentration of plasma glucose (see Supplementary Fig. S2a). This treatment effect 
was lost when empagliflozin was co-administered with metformin and absent in metformin-treated mice (see 
Supplementary Fig. S2b,c). These observations with respect to glucosuria, measured after six weeks of treatment, 
were also evident after two weeks of treatment (data not shown). Cytosolic glucose concentrations within renal 
cortices, determined in tissue that was harvested from fasted mice ~24 h after the last dose, were increased in all 
db/db mice compared to db/m, and exacerbated by metformin mono-therapy (Fig. 3d). Empagliflozin, either as a 
mono-therapy or co-therapy with metformin, did not reduce cortical glucose content (Fig. 3d).
Compared with db/m mice, the expression of genes encoding SGLT1 (Slc5a1), SGLT2 (Slc5a2), and GLUT2 
(Slc2a2) were elevated in all diabetic mice, except for those administered co-therapy (Fig. 4a–c). Co-treatment 
substantially reduced the diabetes-induced upregulation of Slc2a2, but not Slc5a1 and Slc5a2, mRNA levels when 
compared to all other diabetic arms (Fig. 4a–c). In non-diabetic db/m mice, empagliflozin tended to increase gene 
expression of Slc5a1 (P = 0.091), but did not affect Slc5a2 and Slc2a2 expression (Fig. 4a–c). Renal cortical protein 
concentration of SGLT2, in total cell membranes, was not different between groups (Fig. 4d,e).
Renal cortical expression of Pck1, encoding a key gluconeogenic enzyme, PEPCK, was increased in all db/db 
groups (Fig. 5a). Fbp1, which encodes the rate-limiting fructose-1,6-bisphosphatase 1 enzyme, was also increased 
in metformin and tended to be increased in co-treated (P = 0.097) diabetic mice (Fig. 5b). G6pc, encoding 
for the enzyme, glucose-6-phophatase, tended to be increased in co-treated mice only (P = 0.067, Fig. 5c). 
Metformin-treated db/db mice tended to have greater expression of Pck1 and Fbp1 when compared to diabetic 
mice treated with empagliflozin (P = 0.051 and P = 0.062, Fig. 5a,b).
Renal function. All db/db mice had albuminuria at two, six and 10 weeks of treatment which remained 
unaffected by any treatment regimen (Fig. 6a–c). Empagliflozin in the non-diabetic db/m mice increased urinary 
albumin excretion by > 2-fold at 6 weeks of treatment (Fig. 6b), due to a similar increase in urine production (see 
above; Table 1). Urinary excretion of renal tubule damage markers, KIM-1 and NGAL, were ~40 times higher 
in db/db vs db/m, without an effect of treatment (Fig. 6d,e). Urinary NGAL in non-diabetic mice treated with 
empagliflozin was also increased; attributed to increased urine production (see above; Table 1). In all db/db mice, 
except those treated with the combination therapy, plasma cystatin C was reduced by ~22%, indicative of glo-
merular hyperfiltration (Fig. 6f). In db/m mice, empagliflozin tended to increase plasma cystatin C levels (+ 17%, 
P = 0.064, Fig. 6f), suggesting a small decrease in GFR.
Renal morphology and expression of profibrotic genes. Compared to db/m, kidney 
weight was ~23% greater in db/db vehicle-, empagliflozin-, and co-treated mice but 43% greater in 
metformin-treated mice (Table 1). Glomerulosclerosis (PAS-positive staining) was elevated in all db/
db mice and unaffected by treatment (Fig. 7a,b). Glomerular collagen IV and fibronectin accumula-
tion tended to be higher in vehicle-treated diabetic vs non-diabetic mice (P = 0.054 and P = 0.095, 
www.nature.com/scientificreports/
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respectively, Fig. 7c–f). This diabetes-induced deposition of glomerular collagen IV and fibronectin was 
absent in all treated arms, except for the latter which remained elevated in metformin-treated mice (Fig. 7c-f). 
Total collagen accumulation within renal cortical/outer medullary regions was increased in all db/db  
mice compared to db/m when quantified using Masson’s trichrome (P < 0.05), but not Sirius Red, staining 
(Fig. 8a–d). Co-treatment with empagliflozin and metformin tended to reduce Masson’s trichrome positivity 
(P = 0.088) and significantly decreased Sirius Red staining when compared to db/db vehicle (Fig. 8a–d). The 
degree of tubulointerstitial collagen IV and fibronectin staining, however, was not different among groups 
(Fig. 8e–h).
Renal cortical expression of ColIVα1, Fn1, Ctgf, Tgfβ1, and the cell surface macrophage marker, Cd14, were 
elevated in vehicle-treated diabetic vs non-diabetic mice (Fig. 9a–e). In mice treated with empagliflozin, the 
diabetes-induced upregulation of Tgfβ1 and Cd14 was absent and there was a trend for reduced Fn1 expression 
compared to vehicle-treated db/db mice (P = 0.059, Fig. 9b,d,e). ColIVα and Ctgf, however, remained elevated in 
empagliflozin-treated diabetic vs non-diabetic mice (Fig. 9a,c). Metformin did not restore the diabetes-induced 
upregulation of any genes but tended to decrease Fn1 (P = 0.095) and Tgfβ1 (P = 0.068) compared to db/db vehi-
cle (Fig. 9a–e). Co-administration of empagliflozin and metformin provided the greatest benefits, such that the 
diabetes-induced upregulation of all genes was no longer present in this group, except for Ctgf expression which 
remained elevated compared to non-diabetic levels (Fig. 9a–e). Ctgf expression was, however, reduced when 
compared to other db/db groups (P = 0.096 vs vehicle, P < 0.05 vs empagliflozin, P = 0.070 vs metformin, Fig. 9c). 
Of note, in non-diabetic mice, empagliflozin increased the renal cortical expression of ColIVα1 but did not affect 
the expression of any other genes (Fig. 9a–e).
Plasma renin activity, and intra-renal renin activity and angiotensin II content. Plasma renin 
activity tended to increase in diabetic vs non-diabetic vehicle-treated counterparts (P = 0.058, Fig. 10a). 
Empagliflozin treatment increased plasma renin activity in non-diabetic mice, and both empagliflozin (P = 0.059) 
and metformin mono-therapies exacerbated this diabetes-induced increase (Fig. 10a). Renin activity in renal 
cortices was not different between non-diabetic and diabetic mice administered with vehicle (Fig. 10b). However, 
empagliflozin increased intra-renal renin activity levels in both non-diabetic and diabetic mice (Fig. 10b). 
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Figure 3. Filtered glucose load, glucosuria, and cortical glucose content. Predicted filtered glucose load 
determined by (a) fasted plasma glucose and (b) GFR on dual y-axes figures, (c) urinary glucose excretion, 
and (d) cytosolic glucose levels within kidney cortices in db/m (open) and db/db (grey) mice. Circles (ο 
) vehicle-treated; squares (◽) empagliflozin-treated; triangles (▵) metformin-treated; and diamonds (⬨) 
empagliflozin + metformin co-treated. Data are (a,b) means ± SEM or (c,d) individual mice with means ± SEM 
(n = 5–11). *P < 0.05 vs db/m vehicle, †P < 0.05 vs db/db vehicle, δP < 0.05 vs db/db metformin by one-way 
ANOVA and Tukey’s post hoc. Comparisons by Student’s unpaired t-test: significance denoted by solid lines and 
trends denoted by dashed lines.
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Combination therapy exacerbated this increase in cortical renin activity but metformin mono-therapy had no 
effect compared to vehicle-treated diabetic mice (Fig. 10b). Renal cortical levels of angiotensin II were not differ-
ent between db/m and db/db vehicle-treated mice, however, an increasing trend was seen in the metformin-treated 
group vs db/m vehicle (P = 0.096) and db/db empagliflozin (P = 0.055, Fig. 10c).
Discussion
In the present study, we demonstrate in the db/db mouse model of type 2 diabetes that upregulation of some 
profibrotic genes in the kidney was ameliorated upon SGLT2 inhibition, parallel to the effects of metformin. 
Figure 4. mRNA and protein expression of glucose transporters in kidney cortices. (a–c) Real-time qPCR 
for Slc5a1 (encoding SGLT1), Slc5a2 (encoding SGLT2), and Slc2a2 (encoding GLUT2), and (d,e) Western 
immunoblot for total cell membrane SGLT2 expression in db/m (open) and db/db (grey) mice. Data are 
means ± SEM (n = 4–6). *P < 0.05 vs db/m vehicle, δP < 0.05 vs db/db metformin by one-way ANOVA and 
Tukey’s post hoc. Comparisons by Student’s unpaired t-test: significance denoted by solid lines and trends 
denoted by dashed lines. Blot has been cropped to improve clarity; see Supplementary Fig. S3 for full length 
blots.
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When empagliflozin and metformin were co-administered, additional molecular and histological markers of 
kidney fibrosis were attenuated. Diabetes-induced upregulation of renal Cd14 was also no longer present in the 
mice treated with empagliflozin (mono- and co-treatment with metformin), but not metformin, suggesting that 
the aforementioned benefits with SGLT2 inhibition may have been mediated through reduced inflammation. 
However, empagliflozin did not improve diabetes-induced albuminuria, increased urinary markers of tubule 
damage (KIM-1 and NGAL), renal hypertrophy, or glomerulosclerosis, when administered alone or in com-
bination with metformin. These partial benefits occurred in line with a modest lowering of blood glucose that 
remained above non-diabetic levels. Thus, in light of our findings and others26, who have failed to observe com-
plete restoration of kidney function, the determinants of renoprotection with SGLT2 inhibition in diabetes war-
rant further consideration.
Previously, in db/db mice, the administration of an SGLT2 inhibitor; dapagliflozin in males23 and tofogli-
flozin in females25, prevented progressive albuminuria, parallel to the effect of losartan in the latter study, and 
lowered plasma glucose levels to < 15 mmol/L. In male db/db mice treated with empagliflozin, Lin et al. similarly 
demonstrated reduced albuminuria and glomerulosclerosis, associated with complete amelioration of hypergly-
cemia24. Vallon et al., also demonstrated that empagliflozin administered to male Akita/+ mice, a model of type 
1 diabetes, reduced albuminuria, renal hypertrophy, and markers of inflammation, which was in proportion to 
blood glucose lowering (average ~11 mmol/L)21. The timing and degree of blood glucose lowering, and dose of 
therapy are the major differences between the current study and previous reports of significant renoprotection. 
We commenced treatment two to three weeks later than that of Terami et al.23, Lin et al.24, and Nagata et al.25, and 
plasma glucose remained > 15 mmol/L in our study. The dose of empagliflozin administered to Akita/+ mice in 
Vallon et al. and db/db mice in Lin et al. equates to four to six times that of the current study, which was provided 
ad libitum in food, and likely contributes to the pronounced blood glucose lowering and renoprotection seen in 
those studies21,24. Despite restoration of glycated hemoglobin levels with empagliflozin in our study, it is likely 
that plasma glucose levels fluctuated around the single daily administration, reaching spikes of 18 and 16 mmol/L 
in mono- and co-treated groups, respectively, compared to 6.5 mmol/L in non-diabetic vehicle-treated mice. We 
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Figure 5. mRNA expression of gluconeogenic enzymes in kidney cortices. (a–c) Real-time qPCR for Pck1 
(encoding phosphoenolpyruvate carboxykinase 1; PEPCK), Fbp1 (encoding fructose bisphosphatase 1), 
and G6pc (encoding glucose-6-phosphatase) in db/m (open) and db/db (grey) mice. Data are means ± SEM 
(n = 4–6). *P < 0.05 vs db/m vehicle by one-way ANOVA and Tukey’s post hoc. Comparisons by Student’s 
unpaired t-test: significance denoted by solid lines and trends denoted by dashed lines.
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determined the circulating glucose level 20–24 h after the previous day’s gavage; likely at a peak glucose concen-
tration given that empagliflozin half-life is ~5.6 h in the male mouse. Indeed, the benefits of early and intensive 
blood glucose lowering for microvascular complications are well established27,28 and fluctuations in glucose level 
are known to increase the risk of complications independent of average glucose exposure29. It is therefore likely 
that renal structures remained exposed to hyperglycemia, at least temporally, in this study. We did not assess 
blood glucose variation by continuous monitoring in the present study. In type 2 diabetic patients, twice daily 
treatment with empagliflozin as an add-on to metformin was not superior to once daily treatment in terms of 
blood glucose lowering30. However, long-term microvascular outcomes from this treatment regimen are yet to 
be determined. Future pre-clinical and clinical studies on renal outcomes would benefit from early and multiple 
daily dosing of empagliflozin, continuous glucose monitoring, and the risk to benefit ratio of higher doses closely 
monitored.
We observed that SGLT2 inhibition in db/db mice reduced the filtered glucose load which, based on previ-
ous in vitro findings, was expected to downregulate markers of proximal tubular damage19,31–33, and translate 
into functional improvements for the kidney. However, clinical features of diabetic nephropathy, including albu-
minuria, urinary markers of tubule damage (KIM-1 and NGAL), kidney growth, and glomerulosclerosis were 
not improved in this study, even when empagliflozin was co-administered with metformin. Empagliflozin is 
expected to reduce the tubular max (Tmax) for glucose reabsorption which, together with reduced filtered load, 
would theoretically reduce glucose content within proximal tubule cells. However, in non-diabetic and diabetic 
mice, empagliflozin did not reduce cortical glucose content when compared to vehicle. Whilst the establishment 
of an inward glucose gradient at the basolateral surface may occur with SGLT2 inhibition13, the reduction in 
plasma glucose levels with empagliflozin as well as reduced cortical expression of Slc2a2 (encoding GLUT2) with 
co-therapy, argues against this possibility. Although unlikely to fully account for unchanged cortical glucose con-
tent, an explanation may be enhanced SGLT1-mediated glucose reabsorption, as seen previously under SGLT2 
blockade34. In this study, kidney mRNA levels of three key gluconeogenic enzymes, Pck1, Fbp1, and G6pc, were 
not enhanced by empagliflozin suggesting there was no compensatory increase in renal gluconeogenesis. This is 
in agreement with another study where kidney Pck1 levels were reduced in Akita/+ mice treated with empagli-
flozin21. Endogenous glucose production (EGP) is enhanced by SGLT2 inhibition in humans35,36 and, given the 
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Figure 6. Kidney function. (a–c) Albuminuria, (d) urinary concentrations of kidney injury molecule 1 (KIM-1), 
(e) neutrophil gelatinase-associated lipocalin (NGAL), and (f) plasma cystatin C levels in db/m (open) and db/
db (grey) mice. Circles (ο ) vehicle-treated; squares (◽) empagliflozin-treated; triangles (▵) metformin-treated; 
and diamonds (⬨) empagliflozin + metformin co-treated. Weeks refer to treatment duration. Data are individual 
mice with means ± SEM (n = 5–10). *P < 0.05 vs db/m vehicle, δP < 0.05 vs db/db metformin by one-way 
ANOVA and Tukey’s post hoc. Comparisons by Student’s unpaired t-test: significance denoted by solid lines and 
trends denoted by dashed lines. Headings refer to duration of treatment.
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abovementioned findings in mice, this may primarily be of hepatic origin. We observed that the diabetes-induced 
increase in renal gluconeogenic gene expression (Pck1 and Fbp1) was exacerbated by metformin. This may be 
explained by compensatory EGP from renal sources, if metformin specifically suppresses hepatic gluconeogene-
sis37,38, although this remains to be tested in future studies.
SGLT2 inhibition increased both plasma and intrarenal renin activity in diabetic and non-diabetic mice. In 
line with this, eight-week treatment with empagliflozin in individuals with type 1 diabetes increased circulating 
angiotensin II levels9, albeit, in our study, intrarenal angiotensin II content remained unchanged. Increased RAS 
activity with SGLT2 inhibition is explained by the expected volume depletion with this class of therapy39. Despite 
a tendency for reduced GFR with SGLT2 inhibition, likely due to increased afferent tone via tubuloglomerular 
feedback40, we cannot rule out relevant increases in efferent tone via activation of the RAS; which could increase 
intraglomerular pressure. RAS inhibition may also restore glomerular function independent of increased capil-
lary pressure41 and thus the benefits afforded by dual RAS-SGLT2 inhibition warrant further study. Indeed, in 
Dahl salt-sensitive diabetic rats, maximal renoprotection from glomerular injury, renal fibrosis, and proteinuria 
was achieved when luseogliflozin was combined with the ACE inhibitor, lisinopril42.
In our studies, SGLT2 inhibition increased fasting and glucose-stimulated plasma insulin levels, which was 
most profound in mice that received dual therapy with metformin, and may account for their weight gain over 
time. This is contrary to the weight loss reported in obese individuals treated with an SGLT2 inhibitor7, how-
ever, Lin et al. demonstrated similar increases in plasma insulin and body weight in db/db mice, along with 
improvements in albuminuria and glomerulosclerosis24. Thus, increased body weight cannot account for the 
only modest renoprotective effects of SGLT2 inhibition seen in our study. Of note, as per empagliflozin, the 
anti-hyperglycemic agent metformin was unable to prevent albuminuria but attenuated kidney Fn1 and Tgfβ 
expression. Interestingly, treatment with metformin exacerbated diabetic kidney growth which warrants addi-
tional study.
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We demonstrated efficacy in our studies by the presence of glucosuria in non-diabetic mice that were treated 
with empagliflozin. As seen previously in STZ-diabetic, Akita/+ and db/db mice20,21,24,25, SGLT2 inhibition did 
not exacerbate diabetes-induced glucosuria, which is explained by the reduction in filtered glucose load equalling 
the degree of SGLT2 inhibition. Also, given that GFR remained sufficient, empagliflozin was able to reach the 
brush border membrane of the proximal tubule and exert its intended effects43. The difference in blood glucose 
lowering between empagliflozin mono- and co-treated groups was modest, suggesting that other factors beyond 
glucose lowering may contribute to the superior renal outcomes seen with dual therapy in this study. We observed 
that fasting and glucose-stimulated insulin secretion was considerably increased in the co-treated mice, along 
with increased pancreatic insulin content. Further, the leftward shift in the relationship between plasma glucose 
levels and urinary glucose excretion with empagliflozin was absent in the co-treated mice. The mechanism(s) 
underlying these findings and their relationship, if any, to kidney fibrosis requires additional study.
SGLT2 inhibitors are a new class of anti-diabetic agent and human studies in type 1 and 2 diabetes have 
demonstrated efficacy in blood glucose lowering and acute hemodynamic changes in kidney function9,44. 
Long-term clinical studies on the incidence of microvascular complications, such as diabetic nephropa-
thy, are ongoing and will determine whether SGLT2 inhibitors exert benefits that are superior to traditional 
agents13. While we were unable to show considerable improvements in renal function, the expression of some 
profibrotic genes was reduced with empagliflozin, in line with the effects of first line anti-diabetic agent, met-
formin. Additional molecular and histological benefits where offered when empagliflozin and metformin were 
co-administered. Persistent hyperglycemia and albuminuria-onset prior to commencement of treatment in this 
model rendered our study an interventional rather than a preventative approach. We suggest that a threshold of 
blood glucose lowering may be required to achieve renoprotection in diabetes, which may differ for individual 
parameters, as evidenced by some, but not all, features of kidney disease improving with SGLT2 inhibition in 
our study. Thus, taken together with previous work, we suggest that early, sufficient, and stable blood glucose 
lowering, possibly with multiple agents, including higher- and/or multiple daily-dosing of SGLT2 inhibition in 
combination with RAS blockade, may be required to achieve maximal renoprotection in diabetes.
Methods
Animals. All procedures were performed in accordance with guidelines from the University of Queensland 
and the National Health and Medical Research Council of Australia. All experimental protocols on mice were 
approved by the University of Queensland Animal Ethics Committee. Male BKS.Cg-Dock7m+ /+ Leprdb/J (db/db) 
mice and lean, heterozygote controls (db/m) were purchased from Jackson laboratories (stock number 000642; 
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Bar Harbor, ME, USA). Mice were housed in an environmentally controlled room (constant temperature 22 °C), 
with a 12:12 h light-dark cycle and access to standard chow and tap water ad libitum. At 10 weeks of age, db/db 
and db/m mice were randomized to receive empagliflozin (10 mg/kg/day; provided by Boehringer-Ingelheim, 
Germany) or vehicle (0.5% hydroxyethylcellulose, Sigma-Aldrich, St. Louis, MO, USA) by oral gavage for 10 
weeks, between the hours of 14:00 and 16:00. Additional db/db mice were administered the anti-hyper glycemic 
agent, metformin (250 mg/kg/day; Sigma-Aldrich), or empagliflozin + metformin co-therapy (as per mono-ther-
apy dosages). Body weight and fasting blood glucose were monitored throughout the study. Approximately 24 h 
after the last treatment (20 weeks of age), mice were fasted for ~4 h and anesthetized with sodium pentobarbital 
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Figure 9. Renal cortical expression of profibrotic genes and macrophage marker. Real-time qPCR for (a) 
ColIVα 1 (encoding collagen type IVα 1), (b) Fn1 (encoding fibronectin), (c) Ctgf (encoding connective tissue 
growth factor, (d) Tgf β 1 (encoding transforming growth factor β 1), and (e) Cd14 (encoding CD14) in db/m 
(open) and db/db (grey) mice. Data are means ± SEM (n = 4–6). *P < 0.05 vs db/m vehicle, †P < 0.05 vs db/
db vehicle by one-way ANOVA and Tukey’s post hoc. Comparisons by Student’s unpaired t-test: significance 
denoted by solid lines and trends denoted by dashed lines.
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(150 mg/kg ip; Virbac, Milperra, NSW, Australia). Kidneys and pancreata were excised, snap-frozen in liquid 
nitrogen, or fixed in 10% neutral buffered formalin.
Food and water intake, and blood and urine collection. At two and six weeks of the treatment period, 
mice were weighed and placed individually into metabolic cages for 24 h measurements of food and water intake, 
and urine collection45,46. Blood samples were collected via tail tipping immediately upon removal from metabolic 
cages. Mice were acclimatized to the metabolic cages by placing them in for short daylight periods on two sepa-
rate occasions prior to the 24 h collection.
Glomerular filtration rate. At week eight, GFR was estimated in conscious mice using the transcuta-
neous decay of retro-orbitally injected FITC-sinistrin (10 mg/100 g body weight dissolved in 0.9% NaCl), as 
previously described47. Background signal was recorded for one minute, mice were injected under brief inhaled 
isoflurane anesthesia, and the signal was recorded for 60 min. GFR was calculated using the half-life derived 
from the rate constant (α 2) of the single exponential, excretion phase of the curve and a semi-empirical factor. 
Plasma cystatin C was also measured at the study end, after 10 weeks of treatment (ELISA, BioVendor, Brno, 
Czech Republic).
Oral glucose tolerance test. At week eight, an oral glucose tolerance test (OGTT) was performed follow-
ing a 6 h fast between 08:00–14:00 h48. Blood samples were taken via tail tipping prior to (0 min) and following 
an oral glucose bolus (2 g/kg body wt of 50% w/v D-glucose solution) at 5, 15, 30, 60, and 120 min for determi-
nation of plasma glucose and insulin concentrations. The efficacy of insulin secretion was calculated (insulino-
genic index; Insulin30-Insulin0/Glucose30-Glucose0)49. The ratio of fasting plasma glucose-to-insulin ratio and 
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Figure 10. Circulating and intra-renal RAS. (a) Plasma renin activity, and renal cortical (b) renin activity  
and (c) angiotensin II content in db/m (open) and db/db (grey) mice. Data are (a,b) means ± SEM and  
(c) median ± IQR with min and max values (n = 5–10). *P < 0.05 vs db/m vehicle, †P < 0.05 vs db/db vehicle, 
δP < 0.05 vs db/db metformin by one-way ANOVA and Tukey’s post hoc. (c) Analyzed by Kruskal-Wallis one-
way ANOVA and no significant differences observed. Comparisons by Student’s unpaired t-test: significance 
denoted by solid lines and trends denoted by dashed lines.
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homestatic model of assessment for insulin resistance (HOMA-IR; fasting plasma insulin (μ U/ml) × fasting glu-
cose (mmol/L)/22.5) were also calculated.
Biochemical analyses. Plasma, urinary, and kidney cortical cytosolic (see below for ultracentrifugation; 
‘Western blotting’) glucose concentrations were measured by the glucose oxidase method (Cayman Chemical, 
Ann Arbor, MI, USA). Glycated hemoglobin was measured in whole blood samples using an enzymatic assay 
kit (Crystal Chem Inc., Downers Grove, IL, USA). ELISA kits were used for the measurement of plasma insulin 
(Crystal Chem Inc.), urinary albumin (Bethyl laboratories, Montgomery, AL, USA), kidney injury molecule-1 
(KIM-1; USCN Life Science Inc., Hubei, China), and neutrophil gelatinase-associated lipocalin (NGAL; R&D 
Systems, Minneapolis, MN, USA). Tissue levels of renin and AngII, and plasma levels of renin were determined 
via radioimmunoassay (Prosearch International, Malvern, VIC, Australia)50.
Histology. Paraffin embedded kidney and pancreas sections were used for the blinded assessment of renal 
injury and islet insulin content, respectively. Glomerulosclerotic index (GSI) was evaluated by a semi-quantitative 
method in 20 glomeruli (× 400) per animal using 2 μ m kidney sections stained with Periodic acid-Schiff (PAS)46 
Anti-human collagen IV (1:100 dilution; Abcam, Milton, Cambridge, UK) and anti-human fibronectin (1:500 
dilution; Sigma-Aldrich) were used to assess mesangial expansion in 20 glomeruli (× 400) and tubulointersti-
tial fibrosis in ten cortical/outer medullary fields (× 100) per animal using 4 μ m kidney sections. Total collagen 
accumulation was assessed in ten cortical/outer medullary fields (× 100) per animal using 2 μ m sections stained 
with Masson’s trichrome and 4 μ m sections stained with Sirius Red26,46. Pancreatic insulin content was deter-
mined using anti-human insulin (1:100 dilution; R&D Systems Inc., Minneapolis, MN, USA) in at least 32 islets 
from four to six different mice per group. Immuno-positive staining was revealed with 3,3′ -Diaminobenzidine 
tetrahydrochloride (DAB) solution. All sections were visualized using a Nikon Brightfield or Olympus Virtual 
Slide microscope. Percent of positive staining for Masson’s trichrome, Sirius Red, or DAB (immunohistochemis-
try) was determined using NIS-Elements imaging software (Nikon Instruments Inc.) or ImageJ (Fiji distribution 
package).
Western blotting. Kidney cortices were homogenized in sucrose (250 mM), triethanolamine (10 mM), and 
complete protease inhibitor cocktail using a dounce homogenizer. Homogenates were centrifuged at 6,000 × g for 
10 min and the supernatant ultracentrifuged at 150,000 × g for 1 h to pellet total cell membrane. Lysates (60 μ g for 
SGLT2 and 10 μ g for β -actin) were denatured using 4 × Laemmli buffer (Bio-rad) without β -mercaptoethanol at 
65 °C for 15 min for SGLT2 or with β -mercaptoethanol at 95 °C for 5 min for β -actin. Protein was resolved using 
SDS-PAGE, transferred to PVDF membranes, blocked in 5% skim milk for 1 h, and immunoblotted overnight 
at 4 °C for SGLT2 (anti-rat, 1:1,000, in-house antibody51) or 4 h at room temperature for β -actin (anti-human, 
1:5,000, Abcam).
Real-time qPCR. Total RNA was extracted from kidney cortex using Trizol. cDNA was synthesized using 
MultiScribe first strand cDNA synthesis kit and real-time qPCR performed using pre-designed Taqman Gene 
Expression Assays for Slc5a1 (Mm00451203_m1), Slc5a2 (Mm00453831_m1), Slc2a2 (Mm00446229_m1), Pck1 
(Mm01247058_m1), G6pc (Mm00839363_m1), Fbp1 (Mm00490181_m1), ColIVα1 (Mm01210125_m1), Fn1 
(Mm01256744_m1), Tgfβ1 (Mm01178820_m1), Ctgf (Mm01192932_g1), and Cd14 (Mm00438094_g1, Life 
Technologies, Mulgrave, VIC, Australia). Relative gene expression was quantified using the comparative thresh-
old cycle (Δ Δ Ct) with 18S rRNA (Life Technologies) as the endogenous multiplexed control.
Statistical analyses. Data were analyzed by one-way ANOVA with Tukey’s post hoc (parametric data) or 
Kruskal-Wallis one-way ANOVA with Dunn’s post hoc (non-parametric data). Student’s unpaired t-test was also 
performed for comparisons between two groups. Student’s paired t-test within each group was performed for 
blood glucose change from baseline, and body weight change between weeks five and 10 of treatment. Data are 
expressed as means ± SEM, and P < 0.05 was considered significantly different and P = 0.05–0.099 was consid-
ered a trend.
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